Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business
The model's full reasoning — Q2 2022 call → NOWe need to determine if management describes a mismatch of scale between the company and the demand it is already serving. The key is: management conveys that the company is currently supplying/serving/participating in something enormous relative to its own business, such that even a modest further share would make it several times bigger. Both conditions: (1) already inside it with real business, (2) management draws the size contrast and treats it as the point. Let's scan the transcript for such language. Management talks about various things: SOFR transition, international growth, retail, etc. But is there a specific instance where they say "we are already inside a huge flow, and we've captured only a tiny fraction"? For example, they mention term SOFR licensed to 1,300 firms, used in $1.6 trillion worth of cash products. But that's about licensing, not necessarily about CME's own revenue scale. They also talk about the S&P Dow Jones JV investment, but that's an investment. Look for explicit statements about how small their share is relative to a large market they already serve. For instance, in the context of BrokerTec, they mention cross-selling and new customers, but not a huge disproportion. In the context of the cloud migration, they are building foundation. One possible candidate: the discussion about the transition from LIBOR to SOFR. They say SOFR futures are 134% of Eurodollar futures, and they have incentives. But that's about market share within a product, not about a huge external flow. Another: the international growth, but they don't say "we are only capturing a tiny fraction of the global demand." The question asks: does management describe a mismatch of scale between the company and the demand it is already serving? That is, the company is small relative to the opportunity it is already inside. For example, if they said "we are currently serving only 1% of the global derivatives market, and we are already the largest exchange, so there's a huge multiple ahead." But they don't say that. Look at the answer about the S&P Dow Jones JV: they invested $410 million to keep 27% stake. They say earnings have tripled since 2013. But that's not about a mismatch of scale. Maybe the discussion about the Google investment? They used proceeds to invest in the JV. Not a mismatch.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.